...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Experimental Hematology Oncology >Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
【24h】

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

机译：抗HER2单克隆和双特异性癌症治疗的开发与临床应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.
机译：HER2靶向免疫疗法由单克隆抗体（例如曲妥珠单抗，Pertuzumab），双特异性抗体（例如MM-111，Ertumaxomab）和武装有抗HER2双特异性抗体（HER2BI-AATC）的活化T细胞。 Trastuzumab是一种治疗HER2阳性转移性乳腺癌的经典药物。 Pertuzumab，Trastuzumab和PAClitaxel的合并应用已被提出为HER2阳性晚期乳腺癌的标准治疗。对抗HER2抗体的抗性导致疾病进展。 HER2针对这些患者可能是一个有希望的治疗方法。 Ertumaxomab增强了免疫效应细胞和肿瘤细胞的相互作用。 MM-111同时绑定到HER2和HER3并阻止下游信令。此外，Her2bi-AATC也是HER2阳性癌症的替代治疗方法。在本次审查中，我们总结了近期HER2靶向单克隆抗体（TRASTUZUMAB，PERTUZUMAB和T-DM1）和双特异性抗体（MM-111，ERTUMAXOMAB和HER2BI-AATC）的进步，特别关注临床试验结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号